 Patent Application Title |
Patent App Num. |
Date |
| Polymer for optoelectronic device | 20110108807 | 20110512 | | L is derived from phenylpyridine, tolylpyridine, benzothienylpyridine, phenylisoquinoline, dibenzoquinozaline, fluorenylpyridine, ketopyrrole, 2-(1-naphthyl)benzoxazole)), 2-phenylbenzoxazole, 2 phenylbenzothiazole, coumarin, thienylpyridine, phenylpyridine, benzothienylpyridine, 3 methoxy-2-phenylpyridine, thienylpyridine, phenylimine, vinylpyridine, pyridylnaphthalene, pyridylpyrrole, pyridylimidazole, phenylindole, derivatives thereof or combinations thereof.
... | | Method for extracting and purifying bisbenzylisoquinolines | 20110105755 | 20110505 | | A method for purifying extracted crude d-tetrandrine by dissolving the crude d-tetrandrine powder in ethanol, treating the solution with a decolorizing agent, filtering, reducing the filtered solution under heat and vacuum, cooling the solution, filtering it and drying the filtered cake to yield substantially pure d-tetrandrine.
... | | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | 20110105502 | 20110505 | | The invention relates to pharmaceutical compositions comprising such tetrahydroisoquinolines, and the use of such tetrahydroisoquinolines for therapeutic purposes. The tetrahydroisoquinolines are GlyT1 inhibitors.
... | | (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline | 20110098286 | 20110428 | | This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides a process for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.
... | | Fluorescence quencher molecules | 20110092689 | 20110421 | | Disclosed are pyridinyl-isoquinoline-dione derivatives, methods of producing these derivatives, conjugates comprising the pyridinyl-isoquinoline dione derivatives and (i) a solid support, or (ii) a biomolecule, methods of producing these conjugates as well as the use of these conjugates as quenchers in fluorescence resonance energy transfer (FRET).
... | Subscribe to updates on this page: Isoquinolin RSS  | | Process for producing bicycloaniline derivatives | 20110092520 | 20110421 | | The present invention relates to a process for producing a hydrate of 3-(2,6-dichlorophenyl)-4-imino-7-[(2′-methyl-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinolin]-7′-yl)amino]-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (Compound A) or of a pharmaceutically acceptable salt of Compound A and a crystalline form of Compound A or of a pharmaceutically acceptable salt of Compound A, which are useful in the field of treatment of various cancers as a kinase inhibitor, especially as a Weel kinase inhibitor.
... | | Quinoline or isoquinoline substituted p2x7 antagonists | 20110092481 | 20110421 | | The present invention is related to novel compounds of formula (I) having P2X7 antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans. (I)
... | | Fuel cells | 20110091746 | 20110421 | | This invention provides a redox fuel cell comprising an anode and a cathode separated by an ion selective polymer electrolyte membrane; means for supplying a fuel to the anode region of the cell; means for supplying an oxidant to the cathode region of the cell; means for providing an electrical circuit between the anode and the cathode; a non-volatile catholyte solution flowing in fluid communication with the cathode, the catholyte solution comprising a redox mediator which is at least partially reduced at the cathode in operation of the cell, and at least partially regenerated by, optionally indirect, reaction with the oxidant after such reduction at the cathode, and a transition metal complex of a multidentate N-donor ligand as a redox catalyst catalysing the regeneration of the... | | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | 20110082130 | 20110407 | | are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).
... | | Process for preparation of enantiomerically pure (s)-1-phenyi-1,2,3,4- tetrahydroisoquinoline | 20110077405 | 20110331 | | Process for preparation of (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline wherein 1-phenyl-1,2,3,4-tetrahydroisoquinoline is reacted with D-(−)-tartaric acid in a solvent system comprising of methanol and water, preferably at 3.3:1 to 1:1 volume ratio, the crystallization mixture is left for crystallization and (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline is released from obtained crystalline diastereoisomeric salt according to standard procedures. (S)-1-Phenyl-1,2,3,4-tetrahydroisoquinoline is the intermediate in enantiomeric synthesis of solifenacin.
... | | Processes for preparing tetrahydroisoquinolines | 20110077400 | 20110331 | | Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. Also disclosed are pharmaceutical compositions comprising tetrahydroisoquinolines, methods of using tetrahydroisoquinolines in the treatment of depression and other conditions and methods for obtaining the crystalline form.
... | | One-pot preparation of hexahydroisoquinolines from dihydroisoquinolines | 20110071300 | 20110324 | | The present invention provides an efficient process for the preparation of hexahydroisoquinolines from dihydroisoquinolines. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines.
... | | One-pot preparation of hexahydroisoquinolines from amides | 20110071299 | 20110324 | | The present invention provides an efficient process for the preparation of hexahydroisoquinolines from amides. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines.
... | Subscribe to updates on this page: Isoquinolin RSS | | Process for preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity | 20110065922 | 20110317 | | A process for the preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity is characterized in that 3-(R)-quinuclidinoloxy anion generated in situ from 3-(R)-quinuclidinol in a presence of strong base in polar organic solvent is subject to acylation with (S)-1-phenyl-1,2,3,4-tetrahydroisoquinolinecarbonyl chloride of chemical purity at least 98%, while maintaining constant anion excess in a reaction mixture, and after reaction completion solifenacin base is optionally transformed into solifenacin salt according to standard procedures. (S)-1-Phenyl-1,2,3,4-tetrahydroisoquinolinecarbonyl chloride of chemical purity at least 98% is obtained in a reaction of (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline and molar excess of phosgene in a presence of tertiary aromatic amine in aromatic hydrocarbon, and isolated in a crystalline form.
... | | Bleaching agent comprising cationic 3,4-dihydroisoquinoline derivatives, special alkanol amines and hydrogen peroxide | 20110056508 | 20110310 | | where n is a natural number from 2 to 6. The invention further relates to use of the agent for bleaching hair and to a corresponding method.
... |
| Dihydro)pyrrolo[2,1-a]isoquinolines | 20110039832 | 20110217 | | The invention relates to 5,6-dihydropyrrolo[2,1-a]isoquinoline and pyrrolo[2,1-a]isoquinoline derivatives according to general formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.
... | | Novel tetrahydroisoquinoline derivative | 20110034481 | 20110210 | | R1 represents a phenylaminocarbonyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, a benzoxazol-2-yl group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group A, or the like; R2 independently represents a C1-C6 alkyl group; R3 represents a group represented by the formula —C(═O)—O—R4 or the like; R4 represents a hydrogen atom, a C1-C6 alkyl group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group B, or the like; X represents an oxygen atom, a methylene group, or a group represented by the formula —NH—, or the like; L represents a single bond, a methylene group, or the like; . . . represents a single bond or a... | | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | 20110028475 | 20110203 | | wherein R1, R2, n and B are as defined in the disclosure, their preparation and their use in therapies for the treatment of central nervous system diseases such as vigilance and sleep disorders, narcolepsy, Alzheimer's disease and other dementias, Parkinson's disease, attention disorders in hyperkinetic children, memory and learning disorders, epilepsy, schizophrenia, moderate cognitive disorders, depression, anxiety, sexual dysfunction, dizziness and travel sickness.
... | | Ring-annulated dihydropyrrolo[2,1-alpha]isoquinolines | 20110028450 | 20110203 | | or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.
... | | Regression of established atherosclerotic plaques, and treating sudden-onset asthma attacks, using parp inhibitors | 20110028420 | 20110203 | | A method is disclosed for treating and inducing the regression of established atherosclerotic plaques. A method is disclosed for treating asthma, including treatment of an ongoing asthma attack. In both cases, treatment with PARP inhibitors, such as the PARP inhibitor TIQ-A (Thieno[2,3-c]isoquinolin-5-one), can lead to regression of existing disease and symptoms.
... | | Process for the preparation of 6-substituted-1-(2h)-isoquinolinones | 20110021779 | 20110127 | | wherein R1 and n are as described in the specification. The present invention further relates to novel intermediates which are used in the process according to the invention and to processes for preparing such intermediates.
... | | Substituted tetrahydro-2h-isoquinolin-1-one derivatives, and methods for the production and use thereof | 20110021462 | 20110127 | | These compounds are poly(ADP-ribose) polymerase (PARP) inhibitors.
... | | Pharmaceutical composition containing alpha-adrenergic receptor antagonist and an anti-muscarinic agent and method of improving lower urinary tract symptoms associated with prostatic hypertrophy | 20100331361 | 20101230 | | A pharmaceutical composition including active ingredients of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl-2-methoxybenzene-1-sulfonamide and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester, or their pharmaceutically acceptable salts, provides improvement of lower urinary tract symptoms associated with prostatic hypertrophy. The active ingredients may be administered either simultaneously or at a time interval. The pharmaceutical composition also provides significant improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia having a substantial storage component.
... | | Platinum (ii) isoqulinoline-pyridine-benzene based complexes, methods for making same, and organic light-emitting diodes including such complexes | 20100314994 | 20101216 | | This invention provides a class of organometallic complexes comprising a tridentate isoquinoline-pyridine-benzene based ligand, a mono-dentate ligand and a platinum (II) center which show high emission quantum efficiency and good thermal stability. This invention also discloses organometallic complexes in organic light-emitting diode (OLED) including them.
... | | Process for the preparation of an enantiomeric trisubstituted 3,4-dihydro-isoquinoline derivative | 20100305325 | 20101202 | | The present invention relates to a process for the preparation of the compound of formula (7) which process comprises the hydrogenation of the compound of formula (4) using bis[chloro-1,5-cyclooctadiene-iridium], (S)-i-dicyclohexylphosphino-2-[(S)-α-(dimethylamino)-2-(dicyclohexylphosphino)benzyl]-ferrocene as a catalyst.
... | | Aminoisoquinoline thrombin inhibitor with improved bioavailability | 20100305153 | 20101202 | | The invention relates to the compound N-(2-oxo-2-propoxyethyl)-β-phenyl-D-phenyl-alanyl-N-[(1-amino-6-iso-quinolinyl)methyl]-L-prolinamide or a pharmaceutically acceptable salt thereof, to a pharmaceutical composition comprising said compound, as well as to the use of the compound for the manufacture of a medicament for treating or for preventing thrombin mediated diseases.
... | | Process for the resolution of isoquinoline derivatives | 20100298570 | 20101125 | | A process for the resolution of racemic tetrahydropapaverine with optically active arylpropionic acids is described.
... | | Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof | 20100292250 | 20101118 | | Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.
... | | 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof | 20100292243 | 20101118 | | Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.
... | | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | 20100292242 | 20101118 | | Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention.
... |
Other Directories (alphabetical): , , , , , , , , , , , , , , , , , , , , -
###
This listing is a sample listing of patents related to Isoquinolin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Isoquinolin with additional patents listed. Browse our RSS directory or Search for other possible listings.
|
